logo
Twitter
Discord
Email
logo
QuidelOrtho Corporation

QuidelOrtho Corporation

NASDAQ•QDEL
CEO: Mr. Joseph M. Busky CPA
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1991-02-01
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Contact Information
9975 Summers Ridge Road, San Diego, CA, 92121, United States
858-552-1100
www.quidelortho.com
Market Cap
$1.89B
P/E (TTM)
-1.6
79.7
Dividend Yield
--
52W High
$49.45
52W Low
$19.50
52W Range
28%
Rank44Top 40.4%
4.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$699.90M-3.74%
4-Quarter Trend

EPS

-$10.78+3493.33%
4-Quarter Trend

FCF

-$94.70M-232.63%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Loss Significantly Narrows Nine month net loss reduced to $(1,001.1)M$ from $(1,873.6)M$ previous period, reflecting lower charges recognized.
Goodwill Impairment Declines Goodwill impairment charge dropped to $700.7M$ for nine months, compared to $1.74B$ recognized last year.
Core Labs Revenue Rises Labs segment revenue increased 5% to $1,116.5M$ for nine months, driven by reagents and consumables growth.
Working Capital Improves Working capital reached $598.8M$ as of September 28, 2025, significantly increasing from $220.1M$ year-end.

Risk Factors

Total Revenue Decreases Nine month total revenues fell 3% to $2,006.6M$, impacted by respiratory product variability and pricing pressures.
Donor Screening Portfolio Exits Donor Screening revenue fell 57% to $40.8M$ (9M) due to planned wind-down of U.S. portfolio operations.
Operating Cash Flow Negative Net cash used for operating activities totaled $(26.7)M$ for nine months, contrasting prior period cash generation.
Increased Restructuring Costs Restructuring and integration charges rose to $234.6M$ (9M) due to Optimization Plan and Savanna Exit costs.

Outlook

Optimization Plan Cost Savings Optimization Plan targets $50M$ net cost savings by 2027 through facility rationalization and procurement efforts.
Strategic Focus Shifts Company refocusing Molecular Diagnostics, planning Savanna Exit completion by H1 2027, intending to acquire LEX Diagnostics.
Short-Term Liquidity Secure Cash and Revolving Credit Facility sufficient to fund near-term capital and operating needs for at least 12 months.
Growing Reagent Rentals Increasing reagent rental placements to lower customer upfront costs, growing installed base and recurring revenue streams.

Peer Comparison

Revenue (TTM)

QuidelOrtho CorporationQDEL
$2.72B
-3.6%
Tilray Brands, Inc.TLRY
$1.16B
+5.3%
NovoCure LimitedNVCR
$642.27M
+11.2%

Gross Margin (Latest Quarter)

Viridian Therapeutics, Inc.VRDN
100.0%
+8043.1pp
Celldex Therapeutics, Inc.CLDX
100.0%
+31.9pp
QuidelOrtho CorporationQDEL
93.2%
+44.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RCUS$2.73B-7.7-69.8%10.1%
VRDN$2.64B-7.7-55.1%3.7%
CLDX$1.97B-9.8-27.6%0.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.4%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 28, 2025|Filed: Nov 6, 2025|
    Revenue: $699.90M-3.7%
    |
    EPS: $-10.78+3493.3%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 29, 2025|Filed: Aug 6, 2025|
    Revenue: $615.10M-3.3%
    |
    EPS: $-3.77+71.4%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 30, 2025|Filed: May 8, 2025|
    Revenue: $692.80M-2.4%
    |
    EPS: $-0.19-99.3%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 29, 2024|Filed: Feb 27, 2025|
    Revenue: $2.78B-7.2%
    |
    EPS: $-30.54-20260.0%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 29, 2024|Filed: Nov 8, 2024|
    Revenue: $727.10M-2.3%
    |
    EPS: $-0.30+57.9%
    Miss
  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Aug 1, 2024|
    Revenue: $3.00B-8.2%
    |
    EPS: $-0.15-101.6%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $636.30M-4.3%
    |
    EPS: $-2.20+175.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $709.70M-16.1%
    |
    EPS: $-25.50-3593.2%
    Miss